Muscarinic receptor antagonists in the treatment of overactive bladder (Q33892704)

29 July 2017

1 reference

title

Muscarinic receptor antagonists in the treatment of overactive bladder (English)

1 reference

29 July 2017

Chapple CR

1

1 reference

PubMed ID

10767450

29 July 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

29 July 2017

1 reference

29 July 2017

55

1 reference

29 July 2017

5A Suppl

1 reference

29 July 2017

33-46; discussion 50

1 reference

A review of the quality-of-life aspects of urinary urge incontinence

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

A myogenic basis for the overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

A neurologic basis for the overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

M1 muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [3H]acetylcholine in the rabbit urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutynin : A New Drug with Analgesic and Anticholinergic Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Tolterodine--a new bladder-selective antimuscarinic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Identification and characterization of muscarinic cholinergic receptors in the human urinary bladder and parotid gland

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Mini-pig urinary bladder function: comparisons of in vitro anticholinergic responses and in vivo cystometry with drugs indicated for urinary incontinence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Pharmacological effects of tolterodine on human isolated urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Idiopathic bladder hyperactivity treated with Ditropan (oxybutynin chloride)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Characterization of the Oxybutynin Antagonism of Drug-Induced Spasms in Detrusor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Comparative in vitro effects of imipramine, oxybutynin, and flavoxate on rabbit detrusor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Anticholinergic medication for the unstable bladder: prospective trials of imipramine/propantheline versus penthienate and oxybutynin versus penthienate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Topical oxybutynin chloride for relaxation of dysfunctional bladders

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

The Use of Intravesical Oxybutynin Chloride in Children with Neurogenic Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

The pharmacokinetics of intravesical and oral oxybutynin chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Intravesical oxybutynin for spinal cord injury patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Intravesical application of oxybutynine: mode of action in controlling detrusor hyperreflexia. Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Treatment of detrusor instability with oxybutynin rectal suppositories

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

The use of salivary stimulant pastilles to improve compliance in women taking oxybutynin hydrochloride for detrusor instability: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Muscarinic acetylcholine receptor subtypes in smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Selective muscarinic receptor agonists and antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

1 reference

7 January 2021

Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Muscarinic antagonists in development for disorders of smooth muscle function

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900492-6

7 January 2021

10.1016/S0090-4295(99)00492-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10767450